GT201000088A - 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa - Google Patents

2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Info

Publication number: GT201000088A
Authority: GT; Guatemala
Prior art keywords: desoxitetrahydrouridins; desaminasa; citidine; fluoro; inhibitors
Prior art date: 2007-10-16

Application number

GT201000088A

Other languages

English (en)

Spanish (es)

Inventor

Gregory S Hamilton

Tsukamoto Takashi

Dana V Ferraris

Duvall Bridget

Lapidus Rena

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-16

Filing date

2010-04-12

Publication date

2012-03-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40251685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000088(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-04-12 Application filed filed Critical

2012-03-13 Publication of GT201000088A publication Critical patent/GT201000088A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

GT201000088A 2007-10-16 2010-04-12 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa GT201000088A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US98039707P	2007-10-16	2007-10-16

Publications (1)

Publication Number	Publication Date
GT201000088A true GT201000088A (es)	2012-03-13

Family

ID=40251685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GT201000088A GT201000088A (es)	2007-10-16	2010-04-12	2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa

Country Status (40)

Country	Link
US (4)	US8268800B2 (2)
EP (2)	EP2207786B1 (2)
JP (2)	JP5496899B2 (2)
KR (1)	KR101543049B1 (2)
CN (1)	CN101827856B (2)
AT (1)	ATE548374T1 (2)
BR (1)	BRPI0818672B8 (2)
CA (1)	CA2702274C (2)
CO (1)	CO6270330A2 (2)
CR (1)	CR11427A (2)
CY (3)	CY1112781T1 (2)
DK (1)	DK2207786T3 (2)
EA (1)	EA018757B1 (2)
EC (1)	ECSP10010095A (2)
ES (2)	ES2384011T3 (2)
FI (2)	FIC20230040I1 (2)
FR (2)	FR23C1052I2 (2)
GT (1)	GT201000088A (2)
HR (1)	HRP20120419T1 (2)
HU (2)	HUS2300045I1 (2)
IL (1)	IL204732A (2)
JO (1)	JO2778B1 (2)
LT (2)	LTPA2023539I1 (2)
LU (2)	LUC00326I9 (2)
ME (1)	ME00997B (2)
MX (1)	MX2010004109A (2)
MY (1)	MY147970A (2)
NI (1)	NI201000055A (2)
NL (2)	NL301257I2 (2)
NO (2)	NO2023048I1 (2)
NZ (1)	NZ584229A (2)
PL (1)	PL2207786T3 (2)
PT (1)	PT2207786E (2)
RS (1)	RS52323B (2)
SA (1)	SA08290661B1 (2)
SI (1)	SI2207786T1 (2)
TW (1)	TWI445539B (2)
UA (1)	UA99476C2 (2)
WO (1)	WO2009052287A1 (2)
ZA (1)	ZA201002178B (2)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8404716B2 (en)	2002-10-15	2013-03-26	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en)	2002-10-15	2021-09-14	Celgene Corporation	Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain Compounds, Compositions and Methods
PL3692983T3 (pl)	2008-05-15	2021-12-27	Celgene Corporation	Doustne formulacje analogów cytydyny i sposoby ich zastosowania
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20100055047A1 (en) *	2008-08-26	2010-03-04	Yiyu Zou	Methods for treating bronchial premalignancy and lung cancer
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
AR076263A1 (es)	2009-04-06	2011-06-01	Eisai Inc	Composiciones y metodos para tratar cancer. uso.
AU2010234562B2 (en) *	2009-04-06	2016-05-12	Taiho Pharmaceutical Co., Ltd.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
AU2010234637B2 (en) *	2009-04-06	2016-05-12	Taiho Pharmaceutical Co., Ltd.	(2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
GB0907551D0 (en)	2009-05-01	2009-06-10	Univ Dundee	Treatment or prophylaxis of proliferative conditions
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
CA2818853A1 (en)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2709613B2 (en)	2011-09-16	2020-08-12	Gilead Pharmasset LLC	Methods for treating hcv
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EP2950786B1 (en)	2013-01-31	2019-11-27	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais
AU2014342402B2 (en)	2013-10-29	2018-11-01	Taiho Pharmaceutical Co., Ltd	Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
SG11201608303QA (en)	2014-04-04	2016-11-29	Del Mar Pharmaceuticals	Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
AU2015305449B2 (en)	2014-08-22	2021-05-06	Celgene Corporation	Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2017096357A1 (en)	2015-12-03	2017-06-08	Epidestiny, Inc.	Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) *	2016-03-16	2017-09-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Cytidine deaminase inhibitors for the treatment of pancreatic cancer
AU2019216531A1 (en)	2018-02-02	2020-09-24	Maverix Oncology, Inc.	Small molecule drug conjugates of gemcitabine monophosphate
CN113227755B (zh) *	2018-08-28	2025-06-27	上海宜晟生物科技有限公司	测定准确度改善
US11224610B2 (en) *	2018-09-19	2022-01-18	Otsuka Pharmaceutical Co., Ltd.	Low dose combination CDA substrate drug/cedazuridine with extended administration
WO2020080912A1 (ko) *	2018-10-19	2020-04-23	인터올리고 주식회사	치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
CN112888700B (zh) *	2018-10-19	2025-03-04	因特欧力多公司	具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
AU2020363412B2 (en) *	2019-10-08	2026-03-12	Taiho Pharmaceutical Co., Ltd.	2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
US12239653B2 (en) *	2020-02-25	2025-03-04	Taiho Pharmaceutical Co., Ltd.	Combination decitabine and cedazuridine solid oral dosage forms
CN117835984A (zh) *	2021-03-26	2024-04-05	克利夫兰诊所基金会	使用胞苷脱氨酶抑制剂治疗rna病毒感染
US20240279266A1 (en) *	2021-05-29	2024-08-22	Msn Laboratories Private Limited, R&D Center	An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
US11938143B2 (en)	2021-10-19	2024-03-26	Akirabio, Inc.	Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250127806A1 (en) *	2021-11-01	2025-04-24	St. John's University	Injectable liquid pharmaceutical composition containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) *	2021-12-25	2023-08-31	Scinopharm Taiwan, Ltd.	Process for preparing cedazuridine
EP4580635A1 (en)	2022-08-31	2025-07-09	Taiho Pharmaceutical Co., Ltd.	Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4017606A (en) *	1973-10-04	1977-04-12	The Upjohn Company	Organic compounds and process
US4210638A (en) *	1978-03-17	1980-07-01	Pcr, Inc.	Antiviral composition and method of treating virus diseases
US4275057A (en) *	1980-01-28	1981-06-23	The United States Of America As Represented By The Department Of Health, Education And Welfare	Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) *	1983-03-10	1985-07-02	Eli Lilly And Company	Difluoro antivirals and intermediate therefor
EP0160079B1 (en)	1983-10-26	1990-01-31	GREER, Sheldon B.	Method and materials for sensitizing neoplastic tissue to radiation
EP0184365B1 (en) *	1984-12-04	1993-08-04	Eli Lilly And Company	Improvements in the treatment of tumors in mammals
US4965374A (en) *	1987-08-28	1990-10-23	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) *	1987-08-28	1993-06-29	Eli Lilly And Company	Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en)	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
EP0543976A4 (en)	1991-04-23	1993-11-10	Oglevee, Ltd.	In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) *	1991-10-08	1993-12-10	Commissariat A Energie Atomique	Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5426183A (en) *	1992-06-22	1995-06-20	Eli Lilly And Company	Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) *	1992-06-22	1997-01-14	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5606048A (en) *	1992-06-22	1997-02-25	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) *	1992-06-22	1998-10-13	Eli Lilly And Company	Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5371210A (en) *	1992-06-22	1994-12-06	Eli Lilly And Company	Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
WO1994019362A1 (en) *	1993-02-23	1994-09-01	City Of Hope	4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en)	1993-05-14	1994-11-24	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) *	1993-06-01	1993-07-21	Hafslund Nycomed As	Cell growth regualtors
US5637688A (en) *	1994-12-13	1997-06-10	Eli Lilly And Company	Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) *	1995-01-18	1996-05-28	Eli Lilly And Company	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) *	1995-03-01	1996-09-06	Human Gene Therapy Research Institute	Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) *	1995-12-13	1999-12-14	Eli Lilly And Company	Process for making gemcitabine hydrochloride
US5760208A (en) *	1996-08-14	1998-06-02	The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations	Process to prepare pyrimidine nucleosides
US6933287B1 (en) *	1999-03-01	2005-08-23	Sheldon B. Greer	Dramatic simplification of a method to treat neoplastic disease by radiation
ATE339960T1 (de) *	1999-03-01	2006-10-15	Halogenetics Inc	Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
EP1207783A1 (en)	1999-08-26	2002-05-29	Aortech International PLC	Improvements relating to catheter positioning
US6462191B1 (en) *	2000-07-13	2002-10-08	Air Products And Chemicals, Inc.	Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
DE60144573D1 (de) *	2000-11-29	2011-06-16	Mitsui Chemicals Inc	Verfahren und Zwischenprodukte bei der Synthese von L-Thymidin
DE60203260T2 (de) *	2001-01-16	2006-02-02	Glaxo Group Ltd., Greenford	Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
EP2322534A1 (en)	2001-05-18	2011-05-18	Rakesh Kumar	Antiviral nucleosides
WO2003012051A2 (en) *	2001-07-31	2003-02-13	The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon	Inhibitor of dna methylation
JP2005522443A (ja)	2002-02-14	2005-07-28	フアーマセツト・リミテツド	改変フッ素化ヌクレオシド類似体
US6982253B2 (en)	2002-06-05	2006-01-03	Supergen, Inc.	Liquid formulation of decitabine and use of the same
CA2499036A1 (en)	2002-09-24	2004-04-08	Koronis Pharmaceuticals, Incorporated	1,3,5-triazines for treatment of viral diseases
WO2004041203A2 (en)	2002-11-04	2004-05-21	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) *	2004-05-06	2012-04-17	University Of Rochester	Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en)	2004-07-13	2006-01-19	Supergen Inc.	Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh)	2004-07-30	2007-11-21	药华医药股份有限公司	β－核苷的立体选择性合成
KR20070073958A (ko)	2004-12-08	2007-07-10	시코르, 인크.	디플루오로뉴클레오시드 및 이의 제조 방법
WO2008085611A2 (en) *	2006-11-27	2008-07-17	University Of Miami	Designer theraphy of pancreatic tumors
WO2009021551A1 (en)	2007-08-13	2009-02-19	Universite De La Mediterranee	A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en)	2007-10-16	2014-03-15	ايساي انك	Certain Compounds, Compositions and Methods
WO2010047698A1 (en)	2008-10-22	2010-04-29	University Of Alabama At Birmingham	Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
AR076263A1 (es) *	2009-04-06	2011-06-01	Eisai Inc	Composiciones y metodos para tratar cancer. uso.
AU2010234637B2 (en) *	2009-04-06	2016-05-12	Taiho Pharmaceutical Co., Ltd.	(2 ' -deoxy-ribofuranosyl) -1,3,4, 7-tetrahydro- (1,3) iazepin-2-0ne derivatives for treating cancer
US8609631B2 (en)	2009-04-06	2013-12-17	Eisai Inc.	Compositions and methods for treating cancer
AU2010234562B2 (en) *	2009-04-06	2016-05-12	Taiho Pharmaceutical Co., Ltd.	Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer

2008
- 2008-10-14 JO JO2008459A patent/JO2778B1/en active
- 2008-10-15 TW TW097139594A patent/TWI445539B/zh active
- 2008-10-16 EP EP08840633A patent/EP2207786B1/en active Active
- 2008-10-16 HR HRP20120419AT patent/HRP20120419T1/hr unknown
- 2008-10-16 ES ES08840633T patent/ES2384011T3/es active Active
- 2008-10-16 MY MYPI2010001528A patent/MY147970A/en unknown
- 2008-10-16 EA EA201000642A patent/EA018757B1/ru unknown
- 2008-10-16 JP JP2010530110A patent/JP5496899B2/ja active Active
- 2008-10-16 NZ NZ584229A patent/NZ584229A/en unknown
- 2008-10-16 US US12/252,961 patent/US8268800B2/en active Active
- 2008-10-16 AT AT08840633T patent/ATE548374T1/de active
- 2008-10-16 MX MX2010004109A patent/MX2010004109A/es active IP Right Grant
- 2008-10-16 RS RS20120232A patent/RS52323B/sr unknown
- 2008-10-16 SI SI200830624T patent/SI2207786T1/sl unknown
- 2008-10-16 CA CA2702274A patent/CA2702274C/en active Active
- 2008-10-16 ME MEP-2010-68A patent/ME00997B/me unknown
- 2008-10-16 PT PT08840633T patent/PT2207786E/pt unknown
- 2008-10-16 ES ES12151552.2T patent/ES2616566T3/es active Active
- 2008-10-16 UA UAA201003977A patent/UA99476C2/ru unknown
- 2008-10-16 DK DK08840633.5T patent/DK2207786T3/da active
- 2008-10-16 BR BRPI0818672A patent/BRPI0818672B8/pt active IP Right Grant
- 2008-10-16 PL PL08840633T patent/PL2207786T3/pl unknown
- 2008-10-16 CN CN2008801117195A patent/CN101827856B/zh active Active
- 2008-10-16 KR KR1020107010621A patent/KR101543049B1/ko active Active
- 2008-10-16 WO PCT/US2008/080163 patent/WO2009052287A1/en not_active Ceased
- 2008-10-16 EP EP12151552.2A patent/EP2447272B1/en active Active
- 2008-10-18 SA SA08290661A patent/SA08290661B1/ar unknown
2010
- 2010-01-26 ZA ZA2010/02178A patent/ZA201002178B/en unknown
- 2010-03-25 IL IL204732A patent/IL204732A/en active IP Right Grant
- 2010-04-09 EC EC2010010095A patent/ECSP10010095A/es unknown
- 2010-04-12 GT GT201000088A patent/GT201000088A/es unknown
- 2010-04-14 NI NI201000055A patent/NI201000055A/es unknown
- 2010-05-12 CR CR11427A patent/CR11427A/es unknown
- 2010-05-13 CO CO10057462A patent/CO6270330A2/es active IP Right Grant
2012
- 2012-05-24 CY CY20121100467T patent/CY1112781T1/el unknown
- 2012-07-24 US US13/556,404 patent/US8618075B2/en active Active
2013
- 2013-11-25 US US14/088,465 patent/US8951987B2/en active Active
2014
- 2014-03-05 JP JP2014043175A patent/JP5859588B2/ja active Active
- 2014-12-29 US US14/584,437 patent/US9567363B2/en active Active
2023
- 2023-12-21 HU HUS2300045C patent/HUS2300045I1/hu unknown
- 2023-12-21 NO NO2023048C patent/NO2023048I1/no unknown
- 2023-12-21 NO NO2023047C patent/NO2023047I1/no unknown
- 2023-12-21 HU HUS2300044C patent/HUS2300044I1/hu unknown
- 2023-12-22 FI FIC20230040C patent/FIC20230040I1/fi unknown
- 2023-12-22 FI FIC20230039C patent/FIC20230039I1/fi unknown
- 2023-12-22 CY CY2023029C patent/CY2023029I1/el unknown
- 2023-12-22 CY CY2023028C patent/CY2023028I1/el unknown
- 2023-12-26 FR FR23C1052C patent/FR23C1052I2/fr active Active
- 2023-12-26 FR FR23C1051C patent/FR23C1051I2/fr active Active
- 2023-12-27 LU LU00326C patent/LUC00326I9/fr unknown
- 2023-12-27 LU LU00327C patent/LUC00327I2/fr unknown
- 2023-12-27 NL NL301257C patent/NL301257I2/nl unknown
- 2023-12-27 NL NL301256C patent/NL301256I2/nl unknown
- 2023-12-29 LT LTPA2023539C patent/LTPA2023539I1/lt unknown
- 2023-12-29 LT LTPA2023538C patent/LTC2207786I2/lt unknown

Also Published As

Publication number	Publication date
CY2023029I1 (el)	2024-02-16
AU2008312435A8 (en)	2014-07-24
US8618075B2 (en)	2013-12-31
FIC20230040I1 (fi)	2023-12-22
LTC2207786I2 (2)	2025-09-10
BRPI0818672B1 (pt)	2020-10-20
ME00997B (me)	2012-10-20
HUS2300045I1 (hu)	2024-01-28
AU2008312435A1 (en)	2009-04-23
EA201000642A1 (ru)	2010-10-29
FR23C1051I2 (fr)	2025-02-07
AU2008312435B2 (en)	2014-04-17
ES2384011T3 (es)	2012-06-28
EP2447272A1 (en)	2012-05-02
US9567363B2 (en)	2017-02-14
LTPA2023538I1 (2)	2024-02-26
CN101827856A (zh)	2010-09-08
CA2702274A1 (en)	2009-04-23
CA2702274C (en)	2015-12-29
ZA201002178B (en)	2011-05-25
US8951987B2 (en)	2015-02-10
JP5859588B2 (ja)	2016-02-10
NO2023047I1 (no)	2023-12-21
BRPI0818672A2 (pt)	2015-04-14
LUC00326I9 (2)	2026-02-25
US20140186335A1 (en)	2014-07-03
MX2010004109A (es)	2010-08-10
FR23C1051I1 (fr)	2024-01-26
ATE548374T1 (de)	2012-03-15
MY147970A (en)	2013-02-28
US20150210730A1 (en)	2015-07-30
JP2011500713A (ja)	2011-01-06
CY2023028I1 (el)	2024-02-16
US20090137521A1 (en)	2009-05-28
IL204732A (en)	2013-07-31
TWI445539B (zh)	2014-07-21
WO2009052287A1 (en)	2009-04-23
HUS2300044I1 (hu)	2024-01-28
NL301256I2 (nl)	2024-01-11
NI201000055A (es)	2010-08-13
KR20100091978A (ko)	2010-08-19
FIC20230039I1 (fi)	2023-12-22
TW200924786A (en)	2009-06-16
KR101543049B1 (ko)	2015-08-07
SI2207786T1 (sl)	2012-10-30
NL301257I2 (nl)	2025-11-06
PL2207786T3 (pl)	2012-09-28
FR23C1052I2 (fr)	2025-02-07
EP2207786B1 (en)	2012-03-07
UA99476C2 (en)	2012-08-27
HK1146410A1 (en)	2011-06-03
IL204732A0 (en)	2010-11-30
CO6270330A2 (es)	2011-04-20
NO2023048I1 (en)	2023-12-21
LUC00326I2 (2)	2026-02-02
JP2014177455A (ja)	2014-09-25
EA018757B1 (ru)	2013-10-30
CY1112781T1 (el)	2016-02-10
PT2207786E (pt)	2012-05-28
US8268800B2 (en)	2012-09-18
ECSP10010095A (es)	2010-07-30
JO2778B1 (en)	2014-03-15
RS52323B (sr)	2012-12-31
NL301256I1 (2)	2024-01-03
US20120289475A1 (en)	2012-11-15
SA08290661B1 (ar)	2012-06-10
JP5496899B2 (ja)	2014-05-21
LUC00327I2 (2)	2026-02-02
HRP20120419T1 (hr)	2012-07-31
ES2616566T3 (es)	2017-06-13
CR11427A (es)	2010-08-16
NZ584229A (en)	2012-06-29
EP2207786A1 (en)	2010-07-21
BRPI0818672B8 (pt)	2021-05-25
CN101827856B (zh)	2013-02-06
DK2207786T3 (da)	2012-06-18
EP2447272B1 (en)	2017-02-01
LTPA2023539I1 (2)	2024-02-26
FR23C1052I1 (fr)	2024-01-26

Publication	Publication Date	Title
GT201000088A (es)	2012-03-13	2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
AR061246A1 (es)	2008-08-13	Anticuerpos anti- dill4 y metodos que los usan
CO6321189A2 (es)	2011-09-20	Compuestos de tiazol y oxazol de bencen-sulfonamida
BR112012008385A2 (pt)	2019-09-24	inibidores de p13 cinase e uso dos mesmos.
CR20160206A (es)	2016-07-11	Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
ECSP099619A (es)	2009-10-30	Anticuerpos anti-robo4 y sus usos
HN2008000179A (es)	2010-06-09	Compuestos triciclicos,composiciones y procedimientos
CR20150088A (es)	2015-04-10	Anticuerpos anti-notch1 nrr
BR112013004341A2 (pt)	2016-05-31	composições pesticidas
CR11861A (es)	2011-02-16	Compuestos organicos
CR20110497A (es)	2011-11-07	Nuevos anticuerpos anti-alfa5beta1 y sus usos
MX338712B (es)	2016-04-28	Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
ECSP077316A (es)	2007-04-26	Compuestos imidazo-3-il-amina bicíclicos sustituidos
PA8792401A1 (es)	2009-03-31	Fenilendiaminas
ECSP11011390A (es)	2012-03-30	Compuestos espiro-amidas sustituidas
CR20110028A (es)	2011-04-07	Derivados de pirimidina como inhibidores de cinasa
CO6450665A2 (es)	2012-05-31	Anticuerpos anti-fgfr3 y métodos que los utilizan
CR20150247A (es)	2015-06-11	Anticuerpos de antihemaglutinina y métodos de uso
CR20150315A (es)	2015-09-16	Biocontrol de nemátodos fitoparásitos mediante paecilomyces
AR059096A1 (es)	2008-03-12	Anticuerpos anti- efrina -b2 y metodos que usan estos
ECSP088743A (es)	2008-10-31	Anticuerpos para egfl7 y métodos para su uso
EP2129672A4 (en)	2009-12-09	ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
ECSP11011486A (es)	2012-03-30	Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
BR112013000779A2 (pt)	2016-06-07	composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BR112013000840A2 (pt)	2016-06-07	método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.